Therefore, it is strongly proposed that n-3 PUFAs could be used as adjuvants for cancer treatments by targeting STAT3 and its downstream signaling proteins, which might be therapeutic targets with a good potential for HCC treatment due to its implication in cell growth and survival. Here, STAT3 is linked to hepatocellular carcinoma.